Physician profile
Danny Song
NPI 1275563041
$31,962.64
in general payments reported to CMS, 2019-2025
14 companies · $26K in 2025
The $26K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.96 · 2021: $111 · 2022: $1,500 · 2023: $3,462 · 2024: $369 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $965 · Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,441.80 |
| Travel and Lodging | $964.83 |
| Food and Beverage | $892.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $13,066.80 | 2025 | Darzalex |
| Glaxosmithkline, LLC. | $12,262.34 | 2025 | |
| Isoray, INC | $4,875.00 | 2022-2023 | Brachytherapy Source |
| Bioprotect Medical, INC. | $1,139.28 | 2025 | Bioprotect Balloon Implant System |
| Stryker Corporation | $189.36 | 2024 | Cobra |
| Elekta, INC. | $134.26 | 2024 | |
| Vericel Corporation | $111.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $51.96 | 2019 | |
| Boston Scientific Corporation | $51.26 | 2023 | Spaceoar System |
| Sumitomo Pharma America, INC. | $45.50 | 2024 | Orgovyx |
| Blue Earth Diagnostics | $35.59 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.